

Lack of Efficacy of Citalopram in Children With Autism Levels of Repetitive Behavior

Archives of General Psychiatry

66, 583

DOI: [10.1001/archgenpsychiatry.2009.30](https://doi.org/10.1001/archgenpsychiatry.2009.30)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Autism: an emerging "neuroimmune disorder"™ in search of therapy. Expert Opinion on Pharmacotherapy, 2009, 10, 2127-2143.	1.8	69
2	Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior. Archives of General Psychiatry, 2009, 66, 581.	12.3	16
3	Treating Repetitive Behavior in ASD: Citalopram Not Effective. AAP Grand Rounds, 2009, 22, 54-54.	0.0	0
4	A Longitudinal Investigation of Psychotropic and Non-Psychotropic Medication Use Among Adolescents and Adults with Autism Spectrum Disorders. Journal of Autism and Developmental Disorders, 2009, 39, 1339-1349.	2.7	183
5	A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Research, 2010, 3, 1-7.	3.8	45
6	Citalopram efficacy study; interstitial 15q11-q13 duplication mouse. Autism Research, 2009, 2, 238-240.	3.8	1
7	Adjunctive quetiapine may help depression comorbid with pervasive developmental disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1570-1571.	4.8	1
8	Autism. Lancet, The, 2009, 374, 1627-1638.	13.7	597
9	Little Benefit to Revascularization Over Intensive Medical Treatment in Diabetes Mellitus With Coronary Artery Disease. Journal of the National Medical Association, 2009, 101, 975-976.	0.8	0
10	Citalopram Ineffective for Reducing Repetitive Behavior in Autism Spectrum Disorders. Journal of the National Medical Association, 2009, 101, 976.	0.8	0
12	Emerging Pharmacotherapies for Neurodevelopmental Disorders. Journal of Developmental and Behavioral Pediatrics, 2010, 31, 564-581.	1.1	44
14	Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). , 2010, , CD004677.		82
15	Pharmacological management of core and comorbid symptoms in autism-spectrum disorder. Advances in Psychiatric Treatment, 2010, 16, 349-360.	0.5	34
16	Pharmacologic Treatment of Behavioral Symptoms Associated With Autism and Other Pervasive Developmental Disorders. Current Treatment Options in Neurology, 2010, 12, 529-538.	1.8	66
17	Pharmacotherapeutics of Tourette Syndrome and Stereotypies in Autism. Seminars in Pediatric Neurology, 2010, 17, 254-260.	2.0	27
18	Trichotillomania (hair pulling disorder), skin picking disorder, and stereotypic movement disorder: toward DSM-V. Depression and Anxiety, 2010, 27, 611-626.	4.1	181
19	Complementary and Alternative Medicine in Autism: An Evidence-Based Approach to Negotiating Safe and Efficacious Interventions with Families. Neurotherapeutics, 2010, 7, 307-319.	4.4	67
20	Improving the Prediction of Response to Therapy in Autism. Neurotherapeutics, 2010, 7, 232-240.	4.4	19

#	ARTICLE	IF	CITATIONS
21	Comorbid Psychiatric Diagnoses in Preschoolers with Autism Spectrum Disorders. Behavioral Disorders, 2010, 35, 243-254.	1.2	9
22	Emerging drugs for the treatment of symptoms associated with autism spectrum disorders. Expert Opinion on Emerging Drugs, 2010, 15, 481-494.	2.4	29
23	fMRI tracks reductions in repetitive behaviors in autism: Two case studies. Neurocase, 2010, 16, 307-316.	0.6	7
24	Citalopram not effective for repetitive behaviour in autistic spectrum disorders. Evidence-Based Mental Health, 2010, 13, 22-22.	4.5	3
25	Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: A review of current and potentially promising treatment options.. Experimental and Clinical Psychopharmacology, 2010, 18, 184-201.	1.8	74
26	Anxiety Disorders in Children and Adolescents. Current Problems in Pediatric and Adolescent Health Care, 2010, 40, 66-99.	1.7	46
27	Is Ecstasy an Empathogen?. Biological Psychiatry, 2010, 68, 1082-1083.	1.3	3
28	Neurobiological correlates of social functioning in autism. Clinical Psychology Review, 2010, 30, 733-748.	11.4	103
29	Indirect basal ganglia pathway mediation of repetitive behavior: Attenuation by adenosine receptor agonists. Behavioural Brain Research, 2010, 210, 116-122.	2.2	74
30	Repetitive Self-Grooming Behavior in the BTBR Mouse Model of Autism is Blocked by the mGluR5 Antagonist MPEP. Neuropsychopharmacology, 2010, 35, 976-989.	5.4	374
31	Safety and Efficacy of Donepezil in Children and Adolescents with Autism: Neuropsychological Measures. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 43-50.	1.3	51
32	Buspirone for Bruxism in a Child with Pervasive Developmental Disorder-Not Otherwise Specified. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 643-645.	1.3	5
33	The Psychiatric Presentation of Fragile X: Evolution of the Diagnosis and Treatment of the Psychiatric Comorbidities of Fragile X Syndrome. Developmental Neuroscience, 2011, 33, 337-348.	2.0	70
34	Psychopharmacology of Autistic Spectrum Disorders in Children and Adolescents. Pediatric Clinics of North America, 2011, 58, 85-97.	1.8	29
35	Pharmacotherapy for Anxiety Disorders in Children and Adolescents. Pediatric Clinics of North America, 2011, 58, 55-72.	1.8	32
36	Riluzole in Autistic Disorder. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 375-379.	1.3	27
37	Controversies Surrounding Pediatric Psychopharmacology. Advances in Pediatrics, 2011, 58, 153-179.	1.4	7
38	Psychopharmacology in autism: An update. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 18-28.	4.8	66

#	ARTICLE	IF	CITATIONS
39	Increased serotonin axons (immunoreactive to 5-HT transporter) in postmortem brains from young autism donors. <i>Neuropharmacology</i> , 2011, 60, 1347-1354.	4.1	96
40	Focus: Pharmacotherapy of Severe Disruptive Behavioral Symptoms Associated with Autism. <i>Child and Adolescent Psychopharmacology News</i> , 2011, 16, 1-8.	0.1	0
41	mGluR5-Antagonist Mediated Reversal of Elevated Stereotyped, Repetitive Behaviors in the VPA Model of Autism. <i>PLoS ONE</i> , 2011, 6, e26077.	2.5	146
42	Pharmacotherapy of Autism Spectrum Disorders. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2011, 46, 81-88.	0.1	1
43	Pharmacotherapy of Autism Spectrum Disorders. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2011, 46, 88.	0.1	0
44	Medical treatment overview. <i>Current Opinion in Pediatrics</i> , 2011, 23, 621-627.	2.0	25
45	Treatment of comorbid anxiety and autism spectrum disorders. <i>Neuropsychiatry</i> , 2011, 1, 567-578.	0.4	59
46	Aripiprazole: A Review of its Use in the Treatment of Irritability Associated with Autistic Disorder Patients Aged 6-17. <i>Journal of Central Nervous System Disease</i> , 2011, 3, JCNDS.S4140.	1.9	11
47	Reduced transcript expression of genes affected by inherited and de novo CNVs in autism. <i>European Journal of Human Genetics</i> , 2011, 19, 727-731.	2.8	109
48	Annual Research Review: Transgenic mouse models of childhood-onset psychiatric disorders. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2011, 52, 442-475.	5.2	27
49	Comparing residential programmes for adults with autism spectrum disorders and intellectual disability: outcomes of challenging behaviour and quality of life. <i>Journal of Intellectual Disability Research</i> , 2011, 55, 918-932.	2.0	32
50	Open-label riluzole in fragile X syndrome. <i>Brain Research</i> , 2011, 1380, 264-270.	2.2	61
51	Effects of a Family-Implemented Treatment on the Repetitive Behaviors of Children with Autism. <i>Journal of Autism and Developmental Disorders</i> , 2011, 41, 1330-1341.	2.7	57
52	Psychotherapy for Individuals with Autism Spectrum Disorders. <i>Journal of Contemporary Psychotherapy</i> , 2011, 41, 29-36.	1.2	13
53	Phenomenology of Comorbid Autism Spectrum and Obsessive-Compulsive Disorders Among Children. <i>Journal of Developmental and Physical Disabilities</i> , 2011, 23, 543-553.	1.6	58
55	Making a Case to Continue Considering Treatment with Selective Serotonin Reuptake Inhibitors for Children with Autism Spectrum Disorders. <i>Current Psychiatry Reports</i> , 2011, 13, 170-173.	4.5	3
56	Cochrane Review: Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). <i>Evidence-Based Child Health: A Cochrane Review Journal</i> , 2011, 6, 1044-1078.	2.0	7
57	Dystrophic Serotonin Axons in Postmortem Brains from Young Autism Patients. <i>Anatomical Record</i> , 2011, 294, 1653-1662.	1.4	40

#	ARTICLE	IF	CITATIONS
58	Factor Analysis of Repetitive Behaviors in Autism as Measured by the Y-BOCS. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 332-339.	1.8	20
59	A Suicidal Adult in Crisis: An Unexpected Diagnosis of Autism Spectrum Disorder. <i>American Journal of Psychiatry</i> , 2011, 168, 890-892.	7.2	26
60	Treatment of Bipolar Disorder in an Adolescent with Autistic Disorder: A Diagnostic and Treatment Dilemma. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 283-286.	1.3	4
61	A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders. <i>Pediatrics</i> , 2011, 127, e1312-e1321.	2.1	287
62	Phenomenology and measurement of circumscribed interests in autism spectrum disorders. <i>Autism</i> , 2011, 15, 437-456.	4.1	126
63	Stereotypies. , 2011, , 380-388.		2
64	Psychopharmacology in children with intellectual disability. <i>Advances in Psychiatric Treatment</i> , 2011, 17, 32-40.	0.5	2
65	Psychiatric Services for Individuals with Intellectual and Developmental Disabilities: Medication Management. <i>Journal of Mental Health Research in Intellectual Disabilities</i> , 2011, 4, 265-289.	2.0	4
66	Restricted and repetitive behaviors in autism spectrum disorders: A review of research in the last decade.. <i>Psychological Bulletin</i> , 2011, 137, 562-593.	6.1	387
67	Autism and related disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 407-418.	1.8	76
68	The Neurochemistry of Autism. , 2012, , 1012-1020.		0
69	Are Adults Just Big Children?. <i>American Journal of Psychiatry</i> , 2012, 169, 248-250.	7.2	6
70	A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders. <i>American Journal of Psychiatry</i> , 2012, 169, 292-299.	7.2	169
71	Patient Autonomy Investigation Under the Technology-Based Health Care System. <i>Bulletin of Science, Technology and Society</i> , 2012, 32, 163-170.	2.9	1
72	Pharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias. <i>Pediatrics</i> , 2012, 129, e1301-e1310.	2.1	70
73	The Neuropathology of Autism. <i>Scientifica</i> , 2012, 2012, 1-16.	1.7	48
74	Sertraline May Improve Language Developmental Trajectory in Young Children with Fragile X Syndrome: A Retrospective Chart Review. <i>Autism Research & Treatment</i> , 2012, 2012, 1-8.	0.5	37
75	Assessment and Treatment in Autism Spectrum Disorders: A Focus on Genetics and Psychiatry. <i>Autism Research & Treatment</i> , 2012, 2012, 1-11.	0.5	22

#	ARTICLE	IF	CITATIONS
76	Unwanted Interactions Among Psychotropic Drugs and Other Treatments for Autism Spectrum Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 437-440.	1.4	13
77	A Case Series of a Luteolin Formulation (Neuroprotek [®]) in Children with Autism Spectrum Disorders. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 317-323.	2.1	94
78	Sexual Obsessions, Compulsions, Suicidality and Homicidality in an Adolescent Diagnosed with Bipolar Disorder Not Otherwise Specified, Obsessive-Compulsive Disorder, Pervasive Developmental Disorder Not Otherwise Specified, and Mild Mental Retardation. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 250-253.	1.3	13
79	Placebo effect in child and adolescent psychiatric trials. <i>European Neuropsychopharmacology</i> , 2012, 22, 787-799.	0.7	32
80	Social memory, amnesia, and autism: Brain oxytocin secretion is regulated by NAD ⁺ metabolites and single nucleotide polymorphisms of CD38. <i>Neurochemistry International</i> , 2012, 61, 828-838.	3.8	66
81	Psychopharmacology of Autism Spectrum Disorders. <i>Pediatric Clinics of North America</i> , 2012, 59, 175-187.	1.8	41
82	Use of Psychotropic Medication in Children and Adolescents With Autism Spectrum Disorders. <i>Pediatrics</i> , 2012, 130, S69-S76.	2.1	157
83	Measurement of restricted and repetitive behaviour in children with autism spectrum disorder: Selecting a questionnaire or interview. <i>Research in Autism Spectrum Disorders</i> , 2012, 6, 757-776.	1.5	49
84	Overuse of psychotropic medications among children and adolescents with autism spectrum disorders: Perspective from a developing country. <i>Research in Developmental Disabilities</i> , 2012, 33, 563-569.	2.2	30
85	New Models for Considering the Role of Medication in the Treatment and Elucidation of the Etiology of Autism. <i>Current Psychiatry Reports</i> , 2012, 14, 726-731.	4.5	5
86	Targeted treatments in autism and fragile X syndrome. <i>Research in Autism Spectrum Disorders</i> , 2012, 6, 1311-1320.	1.5	41
87	Psychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challenges. <i>Annals of General Psychiatry</i> , 2012, 11, 16.	2.7	152
88	Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. <i>Journal of Neurodevelopmental Disorders</i> , 2012, 4, 19.	3.1	251
89	"The presentation and classification of anxiety in autism spectrum disorder": Commentary.. <i>Clinical Psychology: Science and Practice</i> , 2012, 19, 348-351.	0.9	9
90	Pharmacotherapy to control behavioral symptoms in children with autism. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1615-1629.	1.8	53
91	Further characterization of repetitive behavior in C58 mice: Developmental trajectory and effects of environmental enrichment. <i>Behavioural Brain Research</i> , 2012, 235, 143-149.	2.2	43
92	Psychopharmacology of Autism Spectrum Disorder. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2012, 21, 957-973.	1.9	21
93	New directions in the treatment of autism spectrum disorders from animal model research. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 407-416.	5.0	31

#	ARTICLE	IF	CITATIONS
94	Historical perspectives on the use of therapeutic agents to treat neurodevelopmental disorders. , 0, , 261-272.		0
95	Medication and nutritional treatments for children with ASDs. , 0, , 258-284.		1
96	Service and treatment planning for adults with ASDs. , 0, , 305-326.		1
97	Modeling Restricted Repetitive Behavior in Animals. Autism-open Access, 2012, 01, .	0.2	10
98	Five-Year Follow-up of Preschoolers with Autism and Comorbid Psychiatric Disorders. Behavioral Disorders, 2012, 38, 57-70.	1.2	3
99	Networking in Autism: Leveraging Genetic, Biomarker and Model System Findings in the Search for New Treatments. Neuropsychopharmacology, 2012, 37, 196-212.	5.4	109
100	Psychotropic Medications in Autism: Practical Considerations for Parents. Journal of Autism and Developmental Disorders, 2012, 42, 1249-1255.	2.7	17
101	Evidence-Based Behavioral Interventions for Repetitive Behaviors in Autism. Journal of Autism and Developmental Disorders, 2012, 42, 1236-1248.	2.7	184
102	Psychotropic Medications in Children with Autism Spectrum Disorders: A Systematic Review and Synthesis for Evidence-Based Practice. Journal of Autism and Developmental Disorders, 2012, 42, 1592-1605.	2.7	116
104	Traitement pharmacologique des comportements problématiques associés aux troubles du spectre autistique: revue de la littérature. Neuropsychiatrie De L'Enfance Et De L'Adolescence, 2012, 60, 42-51.	0.2	5
105	Design and Subject Characteristics in the Federally-Funded Citalopram Trial in Children with Pervasive Developmental Disorders. Journal of Autism and Developmental Disorders, 2012, 42, 432-440.	2.7	8
106	Focal brain inflammation and autism. Journal of Neuroinflammation, 2013, 10, 46.	7.2	132
107	Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders. Journal of Developmental and Physical Disabilities, 2013, 25, 355-371.	1.6	16
108	Pediatric Anxiety Disorders. , 2013, , .		2
109	Serotonin Hypothesis of Autism: Implications for Selective Serotonin Reuptake Inhibitor Use during Pregnancy. Autism Research, 2013, 6, 149-168.	3.8	76
110	An Open-Label Pilot Study of a Formulation Containing the Anti-Inflammatory Flavonoid Luteolin and Its Effects on Behavior in Children With Autism Spectrum Disorders. Clinical Therapeutics, 2013, 35, 592-602.	2.5	169
111	A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders. Journal of Autism and Developmental Disorders, 2013, 43, 1017-1027.	2.7	13
112	Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials. Journal of Autism and Developmental Disorders, 2013, 43, 739-746.	2.7	45

#	ARTICLE	IF	CITATIONS
113	Translation of Anxiety Treatment to Youth with Autism Spectrum Disorders. <i>Journal of Child and Family Studies</i> , 2013, 22, 405-413.	1.3	14
114	Pharmacotherapy of autism spectrum disorders. <i>Brain and Development</i> , 2013, 35, 119-127.	1.1	49
115	Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). <i>The Cochrane Library</i> , 2013, , CD004677.	2.8	167
116	Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research. <i>Drugs</i> , 2013, 73, 303-314.	10.9	87
117	Psychopharmacology of autism spectrum disorders: A selective review. <i>Autism</i> , 2013, 17, 645-654.	4.1	25
118	Reduced Serotonin Receptor Subtypes in a Limbic and a Neocortical Region in Autism. <i>Autism Research</i> , 2013, 6, 571-583.	3.8	70
119	The Pharmacoepidemiology of Selective Serotonin Reuptake Inhibitors for Children and Adolescents in Canada from 2005 to 2009: A Database Analysis. <i>Paediatric Drugs</i> , 2013, 15, 319-327.	3.1	27
120	The Developmental Neurobiology of Repetitive Behavior. , 2013, , 761-782.		3
121	Current Trends in the Pharmacological Treatment of Autism Spectrum Disorders. , 2013, , 85-101.		0
122	Alterations of neocortical development and maturation in autism: Insight from valproic acid exposure and animal models of autism. <i>Neurotoxicology and Teratology</i> , 2013, 36, 57-66.	2.4	45
123	Autism Spectrum Disorders. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2013, 43, 2-11.	1.7	46
124	Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. <i>Research in Developmental Disabilities</i> , 2013, 34, 2551-2563.	2.2	50
125	Exploring the Manifestations of Anxiety in Children with Autism Spectrum Disorders. <i>Journal of Autism and Developmental Disorders</i> , 2013, 43, 2341-2352.	2.7	149
126	The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: A pilot [¹¹ C]Ro15-4513 positron emission tomography study. <i>Neuropharmacology</i> , 2013, 68, 195-201.	4.1	97
127	Progress toward treatments for synaptic defects in autism. <i>Nature Medicine</i> , 2013, 19, 685-694.	30.7	167
128	The Effect of Cognitive-Behavioral Therapy Versus Treatment as Usual for Anxiety in Children With Autism Spectrum Disorders: A Randomized, Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 132-142.e2.	0.5	205
129	The Development of Targeted Neurobiological Therapies in Child and Adolescent Psychiatry. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 775-779.	0.5	2
130	Clinical characteristics of high-functioning youth with autism spectrum disorder and anxiety. <i>Neuropsychiatry</i> , 2013, 3, 147-157.	0.4	46

#	ARTICLE	IF	CITATIONS
131	Baseline Factors Predicting Placebo Response to Treatment in Children and Adolescents With Autism Spectrum Disorders. <i>JAMA Pediatrics</i> , 2013, 167, 1045.	6.2	49
132	Feasibility of exposure response prevention to treat repetitive behaviors of children with autism and an intellectual disability: A brief report. <i>Autism</i> , 2013, 17, 196-204.	4.1	22
133	Pharmacological Intervention for Disruptive Behaviors in Intellectual and Developmental Disabilities. <i>International Review of Research in Developmental Disabilities</i> , 2013, 44, 281-325.	0.8	4
134	Placebo Response and the Company It Keeps. <i>JAMA Pediatrics</i> , 2013, 167, 1000.	6.2	2
135	Cognitive-Behavioral Therapy for Anxiety in Children With High-Functioning Autism: A Meta-analysis. <i>Pediatrics</i> , 2013, 132, e1341-e1350.	2.1	191
136	Current state and future prospects of pharmacological interventions for autism. <i>Neuropsychiatry</i> , 2013, 3, 245-259.	0.4	4
137	Managing anxiety comorbidity in youth with autism spectrum disorders. <i>Neuropsychiatry</i> , 2013, 3, 411-421.	0.4	11
138	Clinical Approach in Autism: Management and Treatment. , 0, , .		2
139	Autism spectrum disorders: an overview on diagnosis and treatment. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, S62-S72.	1.7	90
140	The evaluation of intellectual and developmental disabilities. , 0, , 200-218.		1
141	Oxotremorine treatment reduces repetitive behaviors in BTBR T+ tf/J mice. <i>Frontiers in Synaptic Neuroscience</i> , 2014, 6, 17.	2.5	27
143	Pharmacotherapy of Anxiety and Repetitive Behaviors in Autism Spectrum Disorders. <i>Child and Adolescent Psychopharmacology News</i> , 2014, 19, 5-9,14.	0.1	2
144	Response inhibition and serotonin in autism: a functional MRI study using acute tryptophan depletion. <i>Brain</i> , 2014, 137, 2600-2610.	7.6	48
145	Overweight and obesity in youth with developmental disabilities: a call to action. <i>Journal of Intellectual Disability Research</i> , 2014, 58, 787-799.	2.0	67
146	Atomoxetine in Autism Spectrum Disorder: No Effects on Social Functioning; Some Beneficial Effects on Stereotyped Behaviors, Inappropriate Speech, and Fear of Change. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 481-485.	1.3	30
147	Psychopharmacological Interventions in Autism Spectrum Disorder. <i>Harvard Review of Psychiatry</i> , 2014, 22, 76-92.	2.1	56
148	Inter-rater Reliability of the Anxiety Disorders Interview Schedule for DSM-IV in High-Functioning Youth with Autism Spectrum Disorder. <i>Journal of Developmental and Physical Disabilities</i> , 2014, 26, 53-65.	1.6	27
149	Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. <i>Psychopharmacology</i> , 2014, 231, 999-1009.	3.1	72

#	ARTICLE	IF	CITATIONS
150	An Update on Medication Management of Behavioral Disorders in Autism. <i>Current Psychiatry Reports</i> , 2014, 16, 437.	4.5	38
151	Assessment and Treatment of Obsessions and Compulsions in Individuals with Autism Spectrum Disorders: a Systematic Review. <i>Review Journal of Autism and Developmental Disorders</i> , 2014, 1, 62-79.	3.4	17
152	Measuring Anxiety as a Treatment Endpoint in Youth with Autism Spectrum Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2014, 44, 1128-1143.	2.7	144
153	Quality of Life in Children and Adolescents with Autism Spectrum Disorders: What Is Known About the Effects of Pharmacotherapy?. <i>Paediatric Drugs</i> , 2014, 16, 123-128.	3.1	19
154	Practice Parameter for the Assessment and Treatment of Children and Adolescents With Autism Spectrum Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 237-257.	0.5	558
155	Future Directions for Research in Autism Spectrum Disorders. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2014, 43, 828-843.	3.4	54
156	Training of child and adolescent psychiatry fellows in autism and intellectual disability. <i>Autism</i> , 2014, 18, 471-475.	4.1	37
157	A Systematic Review of Treatments for Anxiety in Youth with Autism Spectrum Disorders. <i>Journal of Autism and Developmental Disorders</i> , 2014, 44, 3215-3229.	2.7	117
158	Pain and placebo in pediatrics: A comprehensive review of laboratory and clinical findings. <i>Pain</i> , 2014, 155, 2229-2235.	4.2	37
159	Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2014, 44, 981-987.	2.7	25
160	<i>N</i>-Acetylcysteine as Treatment for Self-Injurious Behavior in a Child with Autism. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 231-234.	1.3	20
161	An Analysis of Treatment Efficacy for Stereotyped and Repetitive Behaviors in Autism. <i>Review Journal of Autism and Developmental Disorders</i> , 2014, 1, 143-164.	3.4	25
162	Psychiatric Drugs in Children and Adolescents. , 2014, , .		3
163	Autism spectrum disorder: advances in evidence-based practice. <i>Cmaj</i> , 2014, 186, 509-519.	2.0	158
164	Children's Yale-Brown Obsessive Compulsive Scale in Autism Spectrum Disorder: Component Structure and Correlates of Symptom Checklist. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 97-107.e1.	0.5	55
165	Treating the Whole Person With Autism: The Proceedings of the Autism Speaks National Autism Conference. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2014, 44, 26-47.	1.7	12
166	Internet-Based, Randomized, Controlled Trial of Omega-3 Fatty Acids for Hyperactivity in Autism. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 658-666.	0.5	84
168	Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 28, 1-52.	1.7	100

#	ARTICLE	IF	CITATIONS
169	Practitioner Review: Self-harm and injurious behaviour in children with developmental delay. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2015, 56, 1042-1054.	5.2	45
170	Escitalopram pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 548-554.	1.5	22
171	New Therapeutic Options for Autism Spectrum Disorder: Experimental Evidences. <i>Experimental Neurobiology</i> , 2015, 24, 301-311.	1.6	13
172	Disorder-dissociated effects of fluoxetine on brain function of working memory in attention deficit hyperactivity disorder and autism spectrum disorder. <i>Psychological Medicine</i> , 2015, 45, 1195-1205.	4.5	25
173	An Orally Active Phenylaminotetralin-Chemotype Serotonin 5-HT ₇ and 5-HT _{1A} Receptor Partial Agonist That Corrects Motor Stereotypy in Mouse Models. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1259-1270.	3.5	31
174	Psychotropic Treatment of Autism. <i>Key Issues in Mental Health</i> , 0, , 151-165.	0.6	3
175	Anxiety in youth with autism spectrum disorders: implications for treatment. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1343-1352.	2.8	20
176	Inverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASD. <i>Psychopharmacology</i> , 2015, 232, 2071-2082.	3.1	46
177	Behavioral training reverses global cortical network dysfunction induced by perinatal antidepressant exposure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2233-2238.	7.1	25
178	Repetitive Behaviors in Autism and Obsessive-Compulsive Disorder: New Perspectives from a Network Analysis. <i>Journal of Autism and Developmental Disorders</i> , 2015, 45, 192-202.	2.7	104
179	Evidence-Based Treatments for Autism Spectrum Disorder. <i>Current Treatment Options in Psychiatry</i> , 2015, 2, 38-56.	1.9	25
180	A Case Series of Cognitive-Behavioral Therapy Augmentation of Antidepressant Medication for Anxiety in Children With Autism Spectrum Disorders. <i>Children's Health Care</i> , 2015, 44, 183-198.	0.9	0
182	Effect of Parent Training vs Parent Education on Behavioral Problems in Children With Autism Spectrum Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1524.	7.4	290
183	Measuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder. <i>Autism</i> , 2015, 19, 38-52.	4.1	78
184	An update on anxiety in youth with autism spectrum disorders. <i>Current Opinion in Psychiatry</i> , 2015, 28, 83-90.	6.3	86
185	An update on pharmacotherapy for autism spectrum disorder in children and adolescents. <i>Current Opinion in Psychiatry</i> , 2015, 28, 91-101.	6.3	188
186	Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis. <i>Translational Psychiatry</i> , 2015, 5, e640-e640.	4.8	54
187	Pharmacotherapy in autism spectrum disorder. , 2015, , 43-62.		1

#	ARTICLE	IF	CITATIONS
188	Brain derived neurotrophic factor and serotonin transporter binding as markers of clinical response to fluoxetine therapy in children with autism. <i>Journal of Pediatric Neurology</i> , 2015, 09, 001-008.	0.2	7
189	Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 467-474.	1.3	11
190	Repetitive Behavior in Neurodevelopmental Disorders: Clinical and Translational Findings. <i>The Behavior Analyst</i> , 2015, 38, 163-178.	2.5	20
191	Intervention in the Context of Development: Pathways Toward New Treatments. <i>Neuropsychopharmacology</i> , 2015, 40, 225-237.	5.4	27
192	Action control processes in autism spectrum disorder – Insights from a neurobiological and neuroanatomical perspective. <i>Progress in Neurobiology</i> , 2015, 124, 49-83.	5.7	36
193	The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2015, 56, 444-452.	5.2	247
194	Brain Fires in Autism Spectrum Disorders. , 2016, 13, .		0
196	An Introduction to the Psychopharmacology of Children and Adolescents With Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychiatric Nursing</i> , 2016, 29, 62-71.	1.4	10
197	The Treatment of Anxiety in Autism Spectrum Disorder (TAASD) Study: Rationale, Design and Methods. <i>Journal of Child and Family Studies</i> , 2016, 25, 1889-1902.	1.3	38
198	Repetitive Behavior in Children with Autism Spectrum Disorder: Similarities and Differences with Obsessive-Compulsive Disorder. , 2016, , 39-50.		11
199	Mouse Behavior and Models for Autism Spectrum Disorders. , 2016, , 269-293.		5
200	Autism spectrum disorder clinical trials: One step at a time. <i>Autism</i> , 2016, 20, 131-133.	4.1	3
201	Effect of Parent Training on Adaptive Behavior in Children With Autism Spectrum Disorder and Disruptive Behavior: Results of a Randomized Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 602-609.e3.	0.5	82
202	Evidence-Based Pharmacotherapy for Autism Spectrum Disorders. <i>Current Treatment Options in Psychiatry</i> , 2016, 3, 161-181.	1.9	4
203	Brief Report: Reduced Restricted and Repetitive Behaviors after Pivotal Response Treatment. <i>Journal of Autism and Developmental Disorders</i> , 2016, 46, 2813-2820.	2.7	19
204	Sensitivity of the modified Children’s Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials. <i>Autism</i> , 2016, 20, 145-152.	4.1	7
205	Irritability and Problem Behavior in Autism Spectrum Disorder: A Practice Pathway for Pediatric Primary Care. <i>Pediatrics</i> , 2016, 137, S136-S148.	2.1	76
206	Focus on Autism and Related Conditions. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 3-8.	0.8	4

#	ARTICLE	IF	CITATIONS
207	Psychopharmacological interventions in autism spectrum disorder. Expert Opinion on Pharmacotherapy, 2016, 17, 937-952.	1.8	93
208	Update on psychopharmacology for autism spectrum disorders. Advances in Mental Health and Intellectual Disabilities, 2016, 10, 6-26.	1.1	15
209	Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis. Pediatrics, 2016, 137, S124-S135.	2.1	169
210	Psychopharmacologic intervention for adults with autism spectrum disorder: A systematic literature review. Research in Autism Spectrum Disorders, 2016, 25, 58-75.	1.5	12
211	Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial. Journal of Pediatrics, 2016, 170, 45-53.e4.	1.8	70
212	The serotonin system in autism spectrum disorder: From biomarker to animal models. Neuroscience, 2016, 321, 24-41.	2.3	359
213	MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 237-249.	4.8	70
214	Mast cells, brain inflammation and autism. European Journal of Pharmacology, 2016, 778, 96-102.	3.5	98
215	Pharmacogenomics of autism spectrum disorder. Pharmacogenomics, 2017, 18, 403-414.	1.3	17
216	Update on Screening, Referring, and Treating the Behavioral, Social, and Mental Health Problems of Very Young Children. Current Treatment Options in Pediatrics, 2017, 3, 15-31.	0.6	4
217	New Assessments and Treatments in ASD. Current Treatment Options in Neurology, 2017, 19, 6.	1.8	10
218	Autism Behavior Inventory: A Novel Tool for Assessing Core and Associated Symptoms of Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 814-822.	1.3	37
219	Body Dysmorphic Disorder in Patients With Autism Spectrum Disorder: A Reflection of Increased Local Processing and Self-Focus. American Journal of Psychiatry, 2017, 174, 313-316.	7.2	12
221	Anxiety Disorders and Obsessive-Compulsive Disorder in Individuals with Autism Spectrum Disorder. Current Psychiatry Reports, 2017, 19, 92.	4.5	118
222	A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research. Paediatric Drugs, 2017, 19, 391-410.	3.1	48
223	Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. Neuropsychopharmacology, 2017, 42, 1390-1398.	5.4	112
224	Risperidone in autism therapy and its efficacy. Learning Disability Practice, 2017, 20, 29-35.	0.1	1
225	A Review of Methods for Monitoring Adverse Events in Pediatric Psychopharmacology Clinical Trials. Drug Safety, 2018, 41, 465-471.	3.2	13

#	ARTICLE	IF	CITATIONS
226	Clinical trials in autism spectrum disorder: evidence, challenges and future directions. <i>Current Opinion in Neurology</i> , 2018, 31, 119-125.	3.6	47
227	An update on pharmacotherapy of autism spectrum disorder in children and adolescents. <i>International Review of Psychiatry</i> , 2018, 30, 78-95.	2.8	103
228	Evaluation and Management of Self-injury in a Child With a Rare Genomic Variant. <i>JAMA Psychiatry</i> , 2018, 75, 524.	11.0	1
229	Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2018, 48, 3711-3719.	2.7	13
230	Parent Education for Young Children With Autism and Disruptive Behavior: Response to Active Control Treatment. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2018, 47, S445-S455.	3.4	19
231	Mindfulness-Based Program for Children with Autism Spectrum Disorder and Their Parents: Direct and Long-Term Improvements. <i>Mindfulness</i> , 2018, 9, 773-791.	2.8	76
232	Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2018, 32, 3-29.	4.0	196
233	Measuring the Effects of Medication for Individuals with Autism. , 2018, , 71-86.		0
234	Understanding Repetitive Behaviors and the Use of Exercise as an Intervention for Adults with Autism Spectrum Disorder and an Intellectual Disability. <i>Critical Reviews in Physical and Rehabilitation Medicine</i> , 2018, 30, 151-179.	0.1	0
235	The Effects of Aerobic Exercise on Repetitive Behaviors and Task Performance for Adults with Autism Spectrum Disorder and an Intellectual Disability. <i>Critical Reviews in Physical and Rehabilitation Medicine</i> , 2018, 30, 323-373.	0.1	0
236	Review of interventions for the management of anxiety symptoms in children with ASD. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 95, 449-463.	6.1	11
237	Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2018, 48, 250-264.	1.7	37
238	Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy. <i>NeuroImmunoModulation</i> , 2018, 25, 300-319.	1.8	50
239	Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. <i>Psychopharmacology</i> , 2018, 235, 3137-3148.	3.1	147
240	Medication Management of Childhood OCD. , 2018, , 155-183.		1
241	Common Defects of Spine Dynamics and Circuit Function in Neurodevelopmental Disorders: A Systematic Review of Findings From in Vivo Optical Imaging of Mouse Models. <i>Frontiers in Neuroscience</i> , 2018, 12, 412.	2.8	34
242	Diagnosis and management of Cornelia de Lange syndrome: first international consensus statement. <i>Nature Reviews Genetics</i> , 2018, 19, 649-666.	16.3	223
243	Low-Dose Fluoxetine in Four Children with Autistic Spectrum Disorder Improves Self-Injurious Behavior, ADHD-Like Symptoms, and Irritability. <i>Case Reports in Psychiatry</i> , 2018, 2018, 1-4.	0.5	4

#	ARTICLE	IF	CITATIONS
244	Autism Spectrum Disorder: Classification, diagnosis and therapy. , 2018, 190, 91-104.		296
245	Depression in Children and Adolescents with Autism Spectrum Disorder. <i>Children</i> , 2018, 5, 112.	1.5	66
246	Systematic review and guide to management of core and psychiatric symptoms in youth with autism. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 379-400.	4.5	37
247	Emotion Regulation Intensive Outpatient Programming: Development, Feasibility, and Acceptability. <i>Journal of Autism and Developmental Disorders</i> , 2019, 49, 495-508.	2.7	25
248	Risk Factors for Unhealthy Weight Gain and Obesity among Children with Autism Spectrum Disorder. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3285.	4.1	69
249	Differential serotonin transporter (5-HTT) and 5-HT ₂ receptor density in limbic and neocortical areas of adults and children with autism spectrum disorders: implications for selective serotonin reuptake inhibitor efficacy. <i>Journal of Neurochemistry</i> , 2019, 151, 642-655.	3.9	13
250	Neurodevelopmental roles and the serotonin hypothesis of autism spectrum disorder. , 2019, , 23-44.		7
251	Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1561.	7.4	60
252	Fluoxetine and Repetitive Behaviors in Children and Adolescents With Autism Spectrum Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1557.	7.4	10
253	Psychopharmacology of neurobehavioral disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2019, 165, 383-390.	1.8	4
254	The psychopharmacology of autism spectrum disorder and Rett syndrome. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2019, 165, 391-414.	1.8	17
255	Selective Serotonin Reuptake Inhibitor Monotherapy for Anxiety Disorders in Children and Adolescents with Autism Spectrum Disorder: A Chart Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 705-711.	1.3	9
256	Effective Medications for Treating Individuals with Autism Spectrum Disorder. <i>Pediatric School Psychology</i> , 2019, , 83-98.	0.0	2
257	Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized <sc>BAART</sc> Clinical Trial. <i>Pharmacotherapy</i> , 2019, 39, 626-635.	2.6	34
258	Depression in Youth with Autism Spectrum Disorder. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2019, 28, 397-409.	1.9	79
259	Reduction of repetitive behavior by co-administration of adenosine receptor agonists in C58 mice. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 181, 110-116.	2.9	17
260	Citalopram attenuates social behavior deficits in the BTBR T+Itpr3tf/J mouse model of autism. <i>Brain Research Bulletin</i> , 2019, 150, 75-85.	3.0	13
261	Rating of the Effectiveness of 26 Psychiatric and Seizure Medications for Autism Spectrum Disorder: Results of a National Survey. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 107-123.	1.3	45

#	ARTICLE	IF	CITATIONS
262	Psychopharmacology of Autism Spectrum Disorders. , 2019, , 158-175.		2
263	Neuroprotective potential of solanesol in intracerebroventricular propionic acid induced experimental model of autism: Insights from behavioral and biochemical evidence. <i>Toxicology Reports</i> , 2019, 6, 1164-1175.	3.3	48
264	Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome. <i>Psychiatric Genetics</i> , 2019, 29, 51-56.	1.1	11
265	Views of Teachers on Anxiety Symptoms in Students with Autism Spectrum Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2019, 49, 704-720.	2.7	15
266	A potential mechanistic role for neuroinflammation in reward processing impairments in autism spectrum disorder. <i>Biological Psychology</i> , 2019, 142, 1-12.	2.2	17
267	The pursuit of the magic pill: the overuse of psychotropic medications in children with intellectual and developmental disabilities in the USA. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 365-368.	3.9	9
268	Network Analysis of Behaviors in the Depression and Autism Realms: Inter-Relationships and Clinical Implications. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 1580-1595.	2.7	41
269	The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 3233-3244.	2.7	33
270	Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. <i>Pediatrics</i> , 2020, 145, .	2.1	621
271	A Pilot Randomized Clinical Trial of a Multidisciplinary Intervention for Encopresis in Children with Autism Spectrum Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 757-765.	2.7	9
272	Recent Advances in the Pharmacological Management of Behavioral Disturbances Associated with Autism Spectrum Disorder in Children and Adolescents. <i>Paediatric Drugs</i> , 2020, 22, 473-483.	3.1	20
273	G Protein-Coupled Receptor Heteromers as Putative Pharmacotherapeutic Targets in Autism. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 588662.	3.7	9
274	Editorial: Targeting the Core Symptoms of Autism Spectrum Disorder With Mechanism-Based Medications. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 816-817.	0.5	4
275	Predictors of Caregiver Strain for Parents of Children with Autism Spectrum Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 3039-3049.	2.7	21
276	Neurological evaluation and management of autism spectrum disorder. , 2020, , 333-347.		0
277	Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B). <i>Contemporary Clinical Trials</i> , 2020, 98, 106103.	1.8	14
278	Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 865-876.	0.5	69
279	Obsessiveâ€“Compulsive Disorder in Autism Spectrum Disorder Across the Lifespan. <i>Psychiatric Clinics of North America</i> , 2020, 43, 745-758.	1.3	4

#	ARTICLE	IF	CITATIONS
280	Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. <i>Molecular Autism</i> , 2020, 11, 66.	4.9	40
281	Talking to Children and Families about Chronic Pain: The Importance of Pain Education—An Introduction for Pediatricians and Other Health Care Providers. <i>Children</i> , 2020, 7, 179.	1.5	17
282	Serotonin differentially modulates the temporal dynamics of the limbic response to facial emotions in male adults with and without autism spectrum disorder (ASD): a randomised placebo-controlled single-dose crossover trial. <i>Neuropsychopharmacology</i> , 2020, 45, 2248-2256.	5.4	7
283	Consensus or chaos: Survey of prescribing practices of New Zealand child and adolescent psychiatrists for children and adolescents with autism spectrum disorder. <i>Research in Autism Spectrum Disorders</i> , 2020, 74, 101553.	1.5	7
284	Recent Developments in Treatment Outcome Measures for Young Children With Autism Spectrum Disorder (ASD). <i>Seminars in Pediatric Neurology</i> , 2020, 34, 100806.	2.0	25
285	Pharmacotherapy of restricted/repetitive behavior in autism spectrum disorder:a systematic review and meta-analysis. <i>BMC Psychiatry</i> , 2020, 20, 121.	2.6	37
286	Evoked Potentials and EEG Analysis in Rett Syndrome and Related Developmental Encephalopathies: Towards a Biomarker for Translational Research. <i>Frontiers in Integrative Neuroscience</i> , 2020, 14, 30.	2.1	17
287	Obsessive—Compulsive Disorder in Autism Spectrum Disorder Across the Lifespan. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2020, 29, 419-432.	1.9	7
288	Treatment in autism spectrum disorder. , 2020, , 193-217.		0
289	Autism spectrum disorder. <i>Nature Reviews Disease Primers</i> , 2020, 6, 5.	30.5	746
290	Symptom scores and medication treatment patterns in children with ADHD versus autism. <i>Psychiatry Research</i> , 2020, 288, 112937.	3.3	6
291	Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 35-45.	0.5	55
292	Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder—Initial Results of a Randomized, Controlled, Crossover, Pilot Study. <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 1392-1399.	2.7	14
293	Dynamic Eye Tracking as a Predictor and Outcome Measure of Social Skills Intervention in Adolescents and Adults with Autism Spectrum Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 1173-1187.	2.7	9
294	Stereotyped Movement Disorder. , 2021, , 4627-4633.		0
295	Obsessive-Compulsive Disorder (OCD). , 2021, , 3212-3214.		0
296	Sameness, Insistence on. , 2021, , 4039-4043.		0
297	Psychopharmacology in Children and Adolescents. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
298	Stereotypies. , 2021, , 451-461.e4.		1
300	Neural Mechanisms Underlying Repetitive Behaviors in Rodent Models of Autism Spectrum Disorders. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 592710.	3.7	40
303	Gender Differences in Treatment-Seeking Youth with Autism Spectrum Disorder. <i>Journal of Child and Family Studies</i> , 2021, 30, 784-792.	1.3	4
304	The Roles of Serotonin in Neuropsychiatric Disorders. <i>Cellular and Molecular Neurobiology</i> , 2022, 42, 1671-1692.	3.3	82
305	Autism and mood disorders. <i>International Review of Psychiatry</i> , 2021, 33, 280-299.	2.8	18
306	Parenting stress in autism spectrum disorder may account for discrepancies in parent and clinician ratings of child functioning. <i>Autism</i> , 2021, 25, 1601-1614.	4.1	14
307	Specialty knowledge and competency standards for pharmacotherapy for pediatric obsessive-compulsive disorder. <i>Psychiatry Research</i> , 2021, 299, 113858.	3.3	3
308	Practitioner's review: medication for children and adolescents with autism spectrum disorder (ASD) and comorbid conditions. <i>Neuropsychiatry</i> , 2021, 35, 113-134.	2.5	13
309	Stereotypies in the Autism Spectrum Disorder: Can We Rely on an Ethological Model?. <i>Brain Sciences</i> , 2021, 11, 762.	2.3	10
310	Rare Opportunities for Insights Into Serotonergic Contributions to Brain and Bowel Disorders: Studies of the SERT Ala56 Mouse. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 677563.	3.7	4
311	Prevalence and profile of depressive mixed state in patients with autism spectrum disorder. <i>Psychiatry Research</i> , 2021, 300, 113932.	3.3	1
312	Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder. <i>Brain Sciences</i> , 2021, 11, 908.	2.3	4
313	The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I: The past and the present. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110326.	4.8	47
314	Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 451-463.	2.9	6
315	Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 4370-4394.	2.7	16
316	Psychotropic Use Among Youths With Intellectual and Developmental Disabilities. <i>Psychiatric Services</i> , 2021, 72, 988-997.	2.0	3
317	Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis. <i>BJPsych Open</i> , 2021, 7, e179.	0.7	20
318	Transition-Age Youth with Autism Spectrum Disorder. , 2021, , 211-235.		1

#	ARTICLE	IF	CITATIONS
319	Subtyping Autism. , 2021, , 4678-4687.		0
320	Pharmacological Treatment of Autism. , 2010, , 245-267.		5
321	Evidence-Based Practices in Autism: Where We Are Now and Where We Need to Go. , 2011, , 365-391.		16
322	Cognitive Behavioral Therapy in High-Functioning Autism: Review and Recommendations for Treatment Development. , 2011, , 197-230.		12
323	Anxiety in Children with Autism Spectrum Disorder. , 2013, , 345-377.		5
324	Behavioral Disorders in Young Children with Autism Spectrum Disorder. Autism and Child Psychopathology Series, 2014, , 563-590.	0.2	5
325	Pharmacotherapy of Behavioral Symptoms and Psychiatric Comorbidities in Adolescents and Adults with Autism Spectrum Disorders. , 2014, , 161-191.		6
326	Phenotypic Variability in Autism Spectrum Disorder: Clinical Considerations. Autism and Child Psychopathology Series, 2014, , 15-29.	0.2	9
327	Obsessions, Compulsions, and Repetitive Behavior: Autism and/or OCD. Autism and Child Psychopathology Series, 2014, , 107-120.	0.2	32
329	Fragile X Syndrome: A Psychiatric Perspective. Results and Problems in Cell Differentiation, 2012, 54, 281-295.	0.7	15
330	Autismus-Spektrum-Störungen. , 2016, , 429-452.		3
331	Autistic Spectrum Disorders and Schizophrenia. , 2011, , 143-162.		1
332	Functional brain abnormalities associated with comorbid anxiety in autism spectrum disorder. Development and Psychopathology, 2020, 32, 1273-1286.	2.3	12
333	The Effect of Music Therapy Along With Play Therapy on Social Behaviors and Stereotyped Behaviors of Children With Autism. Practice in Clinical Psychology, 2017, 5, 251-262.	0.3	3
334	Pharmacotherapy for anxiety disorders in children and adolescents. Dialogues in Clinical Neuroscience, 2011, 13, 439-452.	3.7	39
335	Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues in Clinical Neuroscience, 2012, 14, 263-279.	3.7	102
336	Challenges in the diagnosis and treatment of depression in autism spectrum disorders across the lifespan. Dialogues in Clinical Neuroscience, 2015, 17, 219-227.	3.7	75
337	Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Dialogues in Clinical Neuroscience, 2017, 19, 395-402.	3.7	39

#	ARTICLE	IF	CITATIONS
338	Pharmacotherapy of Autism and Related Disorders. <i>Psychiatric Annals</i> , 2010, 40, 203-209.	0.1	5
339	Evidence-Based Treatment Approach to Autism Spectrum Disorders. <i>Pediatric Annals</i> , 2011, 40, 569-574.	0.8	7
340	Efficacy of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid against Restricted Repetitive Behaviors in Individuals with Autism Spectrum Disorders: A Placebo-Controlled Trial. <i>Journal of Addiction Research & Therapy</i> , 2012, 01, .	0.2	2
341	Aripiprazole Improved Obsessive Compulsive Symptoms in Asperger's Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2011, 9, 134-136.	2.0	3
342	Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. <i>New England Journal of Medicine</i> , 2021, 385, 1462-1473.	27.0	149
345	Psychopharmacology in Children with PDD: Review of Current Evidence. , 2011, , 231-243.		1
346	Autistic Spectrum Disorders. , 2012, , 638-663.		1
348	Pharmacology in the Treatment of Severe Autism Spectrum Disorder. <i>Pediatric Annals</i> , 2012, 41, 1-3.	0.8	0
349	An 11-Year-Old Boy with Tantrums and Head Banging. <i>Pediatric Annals</i> , 2012, 41, 1-3.	0.8	0
350	Treatment Plan for a Patient with an Autism Spectrum Disorder. <i>Pediatric Annals</i> , 2012, 41, 1-3.	0.8	28
351	Counseling and Other Therapeutic Strategies for Children with AS and Their Families. <i>Issues in Children's and Families' Lives</i> , 2013, , 39-63.	0.2	0
352	Inhibitory and Excitatory Systems in Autism Spectrum Disorders. , 2013, , 335-346.		1
356	Current Therapies. , 2015, , 195-207.		0
358	Antidepressiva. , 2016, , 99-185.		1
359	Stereotypies. , 2017, , 407-414.		0
361	Pharmacotherapies for Children with Autism Spectrum Disorder. <i>Child and Adolescent Psychopharmacology News</i> , 2017, 22, 1-11,16.	0.1	0
362	Psychopharmacology of Autism Spectrum Disorder. , 2020, , 385-436.		1
363	Intervention with Self-Injurious Behavior. <i>Autism and Child Psychopathology Series</i> , 2020, , 195-259.	0.2	0

#	ARTICLE	IF	CITATIONS
366	Do Hospital and Community SSRI Usage Patterns in Children and Adolescents Match the Evidence?. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2010, 19, 218-26.	0.6	4
367	Clinical approach to motor stereotypies in autistic children. Iranian Journal of Pediatrics, 2010, 20, 149-59.	0.3	12
369	Pharmacological therapies for autism spectrum disorder: a review. P and T, 2015, 40, 389-97.	0.9	55
370	Treatment of Autism Spectrum Disorder in Children and Adolescents. Psychopharmacology Bulletin, 2016, 46, 18-41.	0.0	64
372	Regulating Together: Emotion Dysregulation Group Treatment for ASD Youth and Their Caregivers. Journal of Autism and Developmental Disorders, 2023, 53, 1942-1962.	2.7	4
373	Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet Psychiatry, the, 2022, 9, 199-210.	7.4	21
375	Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial. Nature Medicine, 2022, 28, 528-534.	30.7	45
376	Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response. Journal of the American Academy of Child and Adolescent Psychiatry, 2023, 62, 151-168.	0.5	22
379	Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors. Journal of Child and Adolescent Psychopharmacology, 2022, 32, 233-241.	1.3	1
380	The Effects of Vitamin Therapy on ASD and ADHD: A Narrative review. CNS and Neurological Disorders - Drug Targets, 2022, 21, .	1.4	1
383	Neural circuits regulating prosocial behaviors. Neuropsychopharmacology, 2023, 48, 79-89.	5.4	23
384	Oxytocin and serotonin in the modulation of neural function: Neurobiological underpinnings of autism-related behavior. Frontiers in Neuroscience, 0, 16, .	2.8	10
386	Therapeutic effects of antidepressants for global improvement and subdomain symptoms of autism spectrum disorder: a systematic review and meta-analysis. Journal of Psychiatry and Neuroscience, 2022, 47, E299-E310.	2.4	7
388	Planning for Treatment of Children with Autism and Other Developmental Disabilities with the Child and Adolescent Psychiatrist. Autism and Child Psychopathology Series, 2022, , 337-363.	0.2	0
389	Clinician- versus caregiver-rated scales as outcome measures of repetitive-restricted behaviors in clinical trials of autism: A systematic review and meta-analysis. European Neuropsychopharmacology, 2023, 70, 56-62.	0.7	0
390	A Critical Review of the Psychomotor Agitation Treatment in Youth. Life, 2023, 13, 293.	2.4	1
391	Qualitative Exploration Toward the Development of a Parent-Rated Scale for Insomnia in Children with Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 0, , .	2.7	2
392	Behavioral regulation by perineuronal nets in the prefrontal cortex of the CNTNAP2 mouse model of autism spectrum disorder. Frontiers in Behavioral Neuroscience, 0, 17, .	2.0	4

#	ARTICLE	IF	CITATIONS
393	PHARMACOLOGICAL TREATMENT OF AUTISM SPECTRUM DISORDERS: DIRECTIONS AND PROSPECTS. International Medical Journal, 2020, , 47-54.	0.0	0
394	A lack of efficacy of continuous theta burst stimulation over the left dorsolateral prefrontal cortex in autism: A double blind randomized sham-controlled trial. Autism Research, 2023, 16, 1247-1262.	3.8	4
395	Psychotropic Medication. Autism and Child Psychopathology Series, 2023, , 527-544.	0.2	0
396	Pharmacotherapy in autism spectrum disorders, including promising older drugs warranting trials. World Journal of Psychiatry, 0, 13, 262-277.	2.7	1
398	Swings and misses with Jeremy Veenstra-VanderWeele. Spectrum, 0, , .	0.0	1
399	Neuroanatomical Alterations in the CNTNAP2 Mouse Model of Autism Spectrum Disorder. Brain Sciences, 2023, 13, 891.	2.3	1
400	The brain serotonin system in autism. Reviews in the Neurosciences, 2023, .	2.9	1
403	Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). The Cochrane Library, 2023, 2023, .	2.8	1
404	A review of the use of psychotropic medication to address challenging behaviour in neurodevelopmental disorders. International Review of Neurobiology, 2023, , 43-65.	2.0	1
405	Telehealth parent training for sleep disturbances in young children with autism spectrum disorder: A randomized controlled trial. Sleep Medicine, 2023, 111, 208-219.	1.6	0
407	Autismus-Spektrum-Störungen. , 2023, , 547-562.		0
408	Antidepressiva. , 2023, , 123-234.		0
409	Lotusine ameliorates propionic acid-induced autism spectrum disorder-like behavior in mice by activating <sc>D1</sc> dopamine receptor in medial prefrontal cortex. Phytotherapy Research, 2024, 38, 1089-1103.	5.8	0
410	Psychopharmacology Management in Autism Spectrum Disorder. Pediatric Clinics of North America, 2024, 71, 283-299.	1.8	0
411	Autismus-Spektrum-Störungen bei Kindern und Jugendlichen. Springer Reference Medizin, 2022, , 1-23.	0.0	0
412	Parental Perspectives on Early Life Screening and Genetic Testing for ASD: A Systematic Review. Journal of Autism and Developmental Disorders, 0, , .	2.7	0
413	Neurodevelopmental Disorders: Autism Spectrum Disorder. , 2023, , 1-54.		0
414	Contribution of the serotonergic system to developmental brain abnormalities in autism spectrum disorder. Autism Research, 0, , .	3.8	0

#	ARTICLE	IF	CITATIONS
415	Review: Dopamine, Serotonin, and the Translational Neuroscience of Aggression in Autism Spectrum Disorder. , 2024, , .		0
416	Pharmacotherapy of Behavioral Symptoms and Psychiatric Comorbidities in Adolescents and Adults with Autism Spectrum Disorders. , 2024, , 207-248.		0